RecruitingNCT06655701
Stress Urinary Incontinence and Sarcopenia in Postmenopausal Osteoporosis
Stress Urinary Incontinence and Sarcopenia in Postmenopausal Osteoporosis: The Intersection of Muscle Loss and Pelvic Dysfunction
Sponsor
Beylikduzu State Hospital
Enrollment
100 participants
Start Date
Nov 15, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
The primary aim of our study is to evaluate the presence of stress urinary incontinence in postmenopausal patients with and without osteoporosis, determine its impact on quality of life, and explore its relationship with sarcopenia.
Eligibility
Sex: FEMALEMin Age: 50 YearsMax Age: 75 Years
Inclusion Criteria5
- Postmenopausal women with DXA measurements performed within the last 6 months.
- Based on DXA measurements:
- Femoral neck and L1-L4 T-scores of -1 and above will be included in the control group (non-osteoporotic).
- Femoral neck and L1-L4 T-scores of -2.5 and below will be included in the osteoporosis group.
- Aged 50-75 years
Exclusion Criteria5
- Refusal to participate in the study.
- History of neurological diseases, infections, surgeries, or trauma that could cause urinary incontinence or muscle loss.
- Presence of psychiatric disorders.
- Cognitive impairments.
- Use of medications that could affect the study results.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TESTNo intervention
No intervention
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06655701
Related Trials
Mechanisms of Anabolic Osteoporosis Therapy
NCT056889691 location
Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis
NCT072426121 location
Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)
NCT055751679 locations
Sequential Therapies After Osteoanabolic Treatment
NCT061647958 locations
Combined Anabolic Therapy
NCT065581881 location